How CellTrio Is Using Robotics to Transform Drug Discovery

What happens when robotics meets life science?

Charlie Duncheon, Founder & CEO of CellTrio, has built a company using robotic automation to help pharmaceutical and life science companies automate cell culturing and biobanking.

CellTrio has raised $18 million and is expanding internationally after building strong demand in the US without a traditional sales team. In this episode, Charlie shares how he acquired and commercialised robotics technology from Korea, why CellTrio is expanding into Asia and Europe, and what it takes to scale a highly specialised B2B technology company.

Andrew Lee Miller also breaks down the marketing strategy CellTrio can use to build a consistent pipeline, strengthen its authority in the life sciences market, and become easier for both customers and AI search tools to discover.

In this episode, we dive into:

Building CellTrio: How Charlie turned robotics technology developed in Korea into a US-focused life science automation company.

Automating Cell Culture: How CellTrio's RoboCell system automates the production of human, animal, and plant cells while reducing human error and contamination.

Automated Biobanking: How robots safely store and retrieve biological samples from cryogenic freezers operating at around -195°C.

Raising $18 Million: Why CellTrio raised capital after establishing strong US demand and how the company is using the funding to expand internationally.

Going Global: How CellTrio is expanding through CellTrio Asia, European orders, new sales hires, and increased manufacturing capacity.

Marketing to a Highly Focused B2B Market: Why companies with a small number of highly valuable customers still need consistent marketing, content, PR, and social media.

Building a Marketing Playbook: Andrew explains why CellTrio should test what works in one market and turn those lessons into a repeatable playbook for international expansion.